Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344475 | 0.84 | PRMT5 (0.46) | PRMT5WDR77ABCB1MEN1KMT2A | |
| SCHEMBL2265663 | 0.84 | P2RX7 (0.48) | NR1H2P2RX7DTYMKTP53ESR2 | |
| SCHEMBL24744821 | 0.81 | NR1H2 (0.40) | NR1H2P2RX7DTYMKTP53MEN1 | |
| SCHEMBL25045380 | 0.81 | NR1H2 (0.41) | NR1H2P2RX7DTYMKTP53MEN1 | |
| SCHEMBL3635546 | 0.79 | P2RX7 (0.45) | NR1H2P2RX7DTYMKTP53MEN1 | |
| SCHEMBL12125488 | 0.79 | NR1H2 (0.43) | NR1H2DTYMKTP53MEN1KMT2A | |
| SCHEMBL1330403 | 0.79 | PRMT5 (0.43) | PRMT5WDR77P2RX7 | |
| SCHEMBL1329966 | 0.79 | NR1H2 (0.39) | NR1H2DTYMKTP53MEN1KMT2A | |
| SCHEMBL31570956 | 0.79 | TSHR (0.44) | NR1H2DTYMKESR2USP2SMN1; SMN2 | |
| SCHEMBL1223408 | 0.78 | ABCB1 (0.51) | PRMT5WDR77ABCB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013204-B1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2543667-B1 | A method of preparing 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2543667-A9 | 2-aminopyridine analogs as glucokinase activators | Array Biopharma, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2013204-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | PRMT5 1697/4885WDR77 2865/4885NR1H2 3726/4885 |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | PRMT5 1465/4885WDR77 2500/4885NR1H2 4452/4885 |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | PRMT5 1465/4885WDR77 2500/4885NR1H2 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.